Hu3F8

BIOLOGICAL3 trials

Sponsors

Memorial Sloan Kettering Cancer Center

Conditions

High-RiskNeuroblastomaNeuroblastoma (NB)

Early Phase 1

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Active, not recruitingNCT03189706

Memorial Sloan Kettering Cancer CenterNeuroblastoma (NB)

Start: 2017-06-12End: 2027-06-01Updated: 2026-07-06

Phase 1

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

CompletedNCT02650648

Memorial Sloan Kettering Cancer CenterHigh-Risk, Neuroblastoma

Start: 2016-01-05End: 2025-07-28Updated: 2025-07-30

Phase 2

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

CompletedNCT03033303

Memorial Sloan Kettering Cancer CenterNeuroblastoma

Start: 2017-01-23End: 2025-09-29Updated: 2025-10-07

Related Papers

A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission

Clinical Cancer Research2025-03-112 citations

Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.

Journal of Clinical Oncology2024-06-012 citations

Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study.

Journal of Clinical Oncology2022-06-0110 citations

Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study.

Journal of Clinical Oncology2019-05-2010 citations